Paris - Delayed Quote EUR

Nanobiotix S.A. (NANO.PA)

Compare
4.4800 +0.0620 (+1.40%)
At close: October 18 at 5:35 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for NANO.PA

Recent News: NANO.PA

View More
Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Na?ve or Resistant to Prior anti-PD-1 Therapy

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Na?ve or Resistant to Prior anti-PD-1 Therapy
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
View More

Related Tickers